IowaBio Bill Tracker - April 5, 2019
Today marks the second funnel deadline, where most bills must be debated in one chamber and out of a committee on the other side, to remain alive. Bills that are placed on the unfinished business calendar, and Ways and Means, Appropriations and Government Oversight bills are still eligible to move forward.
Here are the highlights of bills IowaBio is tracking:
Pharmacy Benefits Manager transparency and rebates SF563/HF489: IowaBio supports this legislation that would create more transparency by requiring PBM disclosure of drug rebate information to the Iowa Insurance Commissioner, and to lower out-of-pocket costs to consumers for prescriptions, have been placed on the unfinished business calendar in both chambers, keeping them alive past the second funnel.
Angel Investor Tax Credit Flexibility HF339/ SF598: These bills IowaBio supports would give IEDA more flexibility to allocate additional tax credit dollars under its cap to the oversubscribed angel investor credits.
Biofuels Excise Tax SSB1246: IowaBio supports this legislation to extend the allowance of lower excise taxes on biodiesel and E-15.
Omnibus Tax Bill/Research Activities Credits SSB1249: Contains provisions clarifying and expanding the research activities tax credit to include “agriscience” and “agricultural animal production”.
Biotech Refocus of Iowa Innovation Corporation and Appropriation: Legislation IowaBio supports to refocus the existing Iowa Innovation Corporation onto biotech companies, SF228/ HF477, and an associated appropriation in SF 608.
Future Ready Iowa: IowaBio supports provisions to fund the Governor’s plan passed last session to reach the goal of ensuring 70 percent of Iowa’s workforce to have education or training beyond high school by 2025 remain alive in appropriations bills SF 608 and HF758.
Empower Rural Iowa HSB204/SSB1193: These ways and means bills IowaBio supports aim to implement the recommendations coming out of the Governor’s Empower Rural Iowa Task Force, to improve rural broadband and tackle the rural workforce housing shortage.
Non-medical switching HF204/SF489: These bills IowaBio supports was narrowed to cover only epilepsy drugs, to ensure continuity of prescriptions for patients stable on a drug; However, the bill had a fiscal note associated that made it difficult for it to move forward.
Newborn screening panel SF564/HF 375: These bills IowaBio supports would expand the state’s infant testing panel to include additional diseases approved at the federal level.
IowaBio’s contingent of Board Members Reed Herzig of Bayer, Troy Arends of Exemplar Genetics and former IowaBio Executive Director Joe Hrdlicka now of Genentech, along with IowaBio Executive Director, Jessica Hyland and Associate Director, Melissa Moyer, participated in the annual BIO Fly-In this week. They spoke with the Iowa delegation about top-priority federal issues including drug pricing, intellectual property protections, and biofuels. They presented Sen. Joni Ernst and Congressman Dave Loebsack with an Innovator in Biotechnology award, which goes to legislators who are champions for the biotechnology industry.